ESPR
Esperion Therapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Jul 15, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.7% | -7.0% | +81.3% | -5.6% | -10.8% | +9.5% | -5.8% | +7.1% | +4.9% | +28.0% | -0.7% | |
| – | -6.0% | -7.9% | +81.8% | -5.6% | -10.9% | +9.9% | -5.7% | +7.5% | +5.2% | -53.4% | +173.7% | |
| – | -17.1% | -28.4% | +175.5% | -16.5% | -23.6% | +0.0% | -20.8% | -24.9% | +7.4% | +81.6% | -7.0% | |
| – | -17.1% | -28.4% | +175.5% | -16.5% | -23.6% | +0.0% | -20.8% | -24.9% | +7.4% | +81.6% | -7.0% | |
| – | +4.5% | +13.8% | +12.6% | +10.5% | +12.4% | +18.2% | +1.4% | +32.5% | +10.4% | +17.8% | -5.6% | |
| – | +12.6% | +27.6% | +11.4% | +15.6% | -5.2% | +18.0% | +5.1% | +15.2% | +23.9% | -25.9% | -0.9% | |
| – | +9,343.8% | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +4.1% | +4.7% | +1.0% | +4.4% | -1.8% | +7.0% | +2.4% | +4.0% | +4.5% | -5.8% | +0.3% | |
| – | +28.5% | +13.4% | +5.3% | +6.6% | -5.4% | +48.4% | +10.0% | +10.3% | +20.2% | -16.2% | -0.1% | |
| – | +61.6% | -4.1% | +26.5% | -94.2% | +2.3% | +1,991.1% | +0.3% | +115.4% | +22.8% | -39.6% | -10.2% | |
| – | +6.7% | +21.0% | -10.4% | +67.7% | -26.9% | +48.1% | +39.4% | +3.8% | +3.8% | -16.1% | +5.1% | |
| – | +0.2% | +0.2% | +0.2% | +0.2% | +0.2% | -9.6% | +0.3% | +2.2% | +2.2% | +0.3% | +0.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.4% | +0.5% | +68.7% | -0.4% | +3.3% | +0.3% | +0.3% | +0.4% | +0.7% | +43.6% | -11.7% |
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.